Cancer cell-dependent increase in senescence-like populations following exosome treatment from bone marrow and induced pluripotent stem cell-derived mesenchymal stem cells

Figure 2 Characterization of exosomes derived from induced pluripotent stem cell-derived mesenchymal stem cells and bone marrow mesenchymal stem cells. A: Flow cytometry analysis showing expression of tetraspanin surface markers CD9, CD81, and CD63 on exosomes using sulfate-latex bead capture; B: Quantification of surface marker expression comparing exosomes derived from induced pluripotent stem cell-derived mesenchymal stem cells (iMSC-Exos) and exosomes derived from bone marrow mesenchymal stem cells (BMSC-Exos); C: Representative transmission electron microscopy images of iMSC-Exos (left) and BMSC-Exos (right). Scale bar = 200 nm; D: Dynamic light scattering profiles depicting size distribution of iMSC-Exos (top) and BMSC-Exos (bottom); E and F: Confocal microscopy images showing uptake of DiI-labeled exosomes (red) by human dermal fibroblasts (E) and human umbilical vein endothelial cells (F). Cells were costained with 5-chloromethylfluorescein diacetate (green) for the cytoplasm and DAPI (blue) for the nuclei. Scale bar = 50 μm. iMSC-Exos: Exosomes derived from induced pluripotent stem cell-derived mesenchymal stem cells; BMSC-Exos: Exosomes derived from bone marrow mesenchymal stem cell; Exos: Exosomes; HDFs: Human dermal fibroblasts; HUVECs: Human umbilical vein endothelial cells.